15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English 存档 1 pvtt-上海中山医院研究-肝癌2
查看: 428|回复: 0

pvtt-上海中山医院研究-肝癌2 [复制链接]

Rank: 10Rank: 10Rank: 10

现金
834 元 
精华
21 
帖子
5573 
注册时间
2001-10-6 
最后登录
2023-11-6 

荣誉之星

1
发表于 2002-10-25 01:07
World J Gastroenterol 2001 Feb;7(1):28-32 Related Articles, Links  

  
Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein.

Fan J, Wu ZQ, Tang ZY, Zhou J, Qiu SJ, Ma ZC, Zhou XD, Ye SL.

Liver Cancer Institute, Zhongshan Hospital, Fudan University Medical Center,136 Yixueyuan Road, Shanghai 200032,China. jiafan 99 @ yahoo.com

AIM: To compare the therapeutic effect and significances of multimodality treatment for hepatocellular carcinoma (HCC) with tumor thrombi in portal vein (PVTT). METHODS: HCC patients (n=147) with tumor thrombi in the main portal vein or the first branch of portal vein were divided into four groups by the several therapeutic methods. There were conservative treatment group in 18 out of patients (group A); and hepatic artery ligation(HAL) and/or hepatic artery infusion (HAI) group in 18 patients (group B), in whom postoperative chemoembolization was done periodically; group of removal of HCC with PVTT in 79 (group C) and group of transcatheter hepatic arterial chemoembolization (TACE) or HAI and/or portal vein infusion (PVI) after operation in 32 (group D). RESULTS: The median survival period was 12 months in our series and the 1-,3-, and 5-year survival rates were 44.3%, 24.5% and 15.2%, respectively. The median survival times were 2, 5, 12 and 16 months in group A, B, C and D, respectively. The 1-, 3- and 5-year survival rates were 5.6%, 0% and 0% in group A; 22.2%, 5.6% and 0% in group B; 53.9%, 26.9% and 16.6% in group C; 79.3%, 38.9% and 26.8% in group D, respectively. Significant difference appeared in the survival rates among the groups (P < 0.05). CONCLUSION: Hepatic resection with removal of tumor thrombi and HCC should increase the curative effects and be encouraged for the prolongation of life span and quality of life for HCC patients with PVTT, whereas the best therapeutic method for HCC with PVTT is with regional hepatic chemotherapy or chemoembolization after hepatic resection with removal of tumor thrombi.

Publication Types:
Clinical Trial
‹ 上一主题|下一主题

肝胆相照论坛

GMT+8, 2024-10-9 10:21 , Processed in 0.013064 second(s), 12 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.